February 20, 2018 / 12:16 PM / 3 months ago

BRIEF-Voyager Therapeutics And Abbvie Announce Global Strategic Collaboration

Feb 20 (Reuters) - Abbvie Inc:

* VOYAGER THERAPEUTICS AND ABBVIE ANNOUNCE GLOBAL STRATEGIC COLLABORATION TO DEVELOP POTENTIAL NEW TREATMENTS FOR ALZHEIMER’S DISEASE AND OTHER TAU-RELATED NEURODEGENERATIVE DISEASES

* VOYAGER THERAPEUTICS INC - VOYAGER TO RECEIVE $69 MILLION UPFRONT PAYMENT AND POTENTIALLY UP TO $155 MILLION IN PRECLINICAL AND PHASE 1 OPTION PAYMENTS

* VOYAGER THERAPEUTICS - IS ALSO ELIGIBLE TO GET UP TO $895 MILLION IN DEVELOPMENT AND REGULATORY MILESTONES FOR EACH VECTORIZED TAU ANTIBODY COMPOUND Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below